NHS Grampian



Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS

Date30th March 2021Our Ref: FA/empTher/RACH/acute/MGPG/781v3.2Enquiries toMGPGExtension56334Direct Line01224 556334Emailgram.mgpg@nhs.scot

Dear Colleague

This letter authorises the extended use of the following guidance until 1st October 2021:

NHS Grampian Staff Empirical Therapy Guidance for Common Infections in Children in the Acute Sector

This guidance remains clinically accurate and relevant, and the review of this guidance will commence shortly.

NOTE: For oral switch option in a penicillin allergic patient being treated for appendicitis, perianal abscess or pilonidal abscess please seek advice from duty medical microbiologist. For treatment of Acute Osteomyelitis/Septic arthritis/Acute discitis/Deep myositis seek advice from duty medical microbiologist for penicillin allergy choice in age >6 months.

If you have any queries regarding this please do not hesitate to contact the Pharmacy and Medicines Directorate.

Yours sincerely

Lesley Coyle Chair of Medicines Guidelines and Policies Group



| Co-ordinators: | Consultation Group: | Approver: |
|--|---|---|
| Fiona McDonald Gillian Macartney, Specialist Pharmacist – Antibiotics | Professor Adilia Warris, Paediatric Infectious Diseases Specialist Dr Ian Gould, Consultant Medical Microbiologist Jenny Mosley, Lead Pharmacist RACH | Chair of Medicine Guidelines and Policies Group |

| Signature: | Signature: | Signature: |
|---------------|--------------------|------------|
| Allen Maartur | Selle Feb 22, 2016 | And |
| Fina McDaald | Torloslay | |

| Identifier: | Review Date: | Date Approved: |
|---------------------------|--------------|----------------|
| NHSG/Guid/Emp/ MGPG781 | October 2017 | October 2015 |

| Uncontrolled when printed Version 3.2 (Amended March 2021) | | |
|---|--|--|
| Executive Sign-Off This document has been endorsed by the Director of Pharmacy and Medicines Management | | |
| | | |

Signature:____

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

This controlled document shall not be copied in part or whole without the express permission of the author or the author's representative.

| Title: | NHS Grampian Staff Empirical Therapy Guidance For Common Infections In Children In The Acute Sector | |
|---|--|--|
| Unique Identifier: | NHSG/Guid/EmpP/MGPG781 | |
| Replaces: | NHSG/Guid/EmpP/MGPG781 v3.1 | |
| Lead Author/Co-ordinator: | Specialist Antibiotic Pharmacists | |
| Subject (as per document registration categories): | Antimicrobial Guidelines | |
| Key word(s): | Antibiotic, Antibiotics, Antimicrobial, Antimicrobials, Infection, Infections, Empirical, Paediatric, Paediatrics, Children, Child, RACH, neonatal, neonates | |
| Policy, Protocol, Procedure or Process Document: | Guideline | |
| Document application: | Whole of Sector | |
| Purpose/description: | To provide guidance on empirical antibiotic therapy for common infections in children to prescribers working in acute hospitals in NHS Grampian. | |
| Responsibility: | Responsibility for the effective management of the Acute Sector's policy, protocol, procedure and process documentation ultimately lies with the General Manager for the Acute Sector. Delegation for formulating, disseminating and controlling these documents falls to either a named individual or a working group. | |
| Policy statement: | It is the responsibility of supervisory staff at all levels to ensure that their staff are working to the most up to date and relevant policies, protocols procedures. By doing so, the quality of the services offered will be maintained, and the chances of staff making erroneous decisions which may affect patient, staff or visitor safety and comfort will be reduced. | |

| Responsibilities for ensuring registration of this document on the NHS Grampian Information/ Document Silo: | | | | |
|---|---|--|--|--|
| Lead Author/Co-ordinator: | Specialist Pharmacist - Antibiotics | | | |
| Physical location of the original of this document: | Pharmacy and Medicines Directorate, Westholme | | | |
| Job title of creator of this document: | Specialist Pharmacist - Antibiotics | | | |
| Job/group title of those who have control over this document: | Specialist Pharmacist - Antibiotics | | | |
| Responsibilities for disseminating document as per distribution list: Lead Author/Co-ordinator: Specialist Pharmacist - Antibiotics | | | | |
| Responsibilities for impleme Organisational: | | | | |

Sector General ManagerHospital/Interface services:Deputy General Managers and Clinical LeadsOperational ManagementUnit Operational ManagersUnit:Clinical LeadsDepartmental:Clinical LeadsArea:Line ManagersReview:Every two years (or sooner if required)

Responsibilities for review of this document:

| Lead Author/Co-ordinator: | Specialist Pharmacist - Antibiotics |
|---------------------------|-------------------------------------|
|---------------------------|-------------------------------------|

Review date:

October 2017

Revision History:

| Revision Date | Previous Revision Date | Summary of ChangesChanges Marked*(Descriptive summary of the changes made)(Identify page numbers and section heading) | |
|-------------------|------------------------------|--|---|
| March 2021 | September 2015 | Update to infective gastroenteritis. | Section 1 – Gastro-intestinal tract and Intra-abdominal (page 4) |
| March 2021 | September 2015 | Update to influenza treatment. | Section 3 – Respiratory (page 10) |
| March 2021 | September 2015 | Removal of Neonatal chlamydia conjunctivitis and Neonatal gonococcal conjunctivitisSection 9 – Eye (page 21) | |
| September 2015 | May 2013 | Refer to Appendix 1 | Whole document |
| September 2015 | May 2013 | Update to influenza treatment. | Section 3 - Respiratory |

| September 2015 | May 2013 | Removal of 2 nd choice antibiotic for <i>staphylococcs aureaus</i> | Section 8 - Musculoskeletal |
|-------------------|----------|---|-----------------------------|
| September 2015 | May 2013 | Removal of neonatal conjuctivitis | Section 9 - Eye |

| Cont | ents | Page Number |
|-------|--|--------------|
| Intro | duction | 2 |
| Dos | ses | 2 |
| Do | cumentation | 2 |
| IV t | o Oral Switch Therapy (IVOST) | 2 |
| Per | nicillin Allergy | 2 |
| | racyclines | |
| | ntamicin and Vancomycin | |
| Adv | /ice | |
| 1. | Gastro-Intestinal Tract and Intra-Abdominal | 4 |
| 2. | Cardiovascular | 8 |
| 3 | Respiratory System | 10 |
| 4 | Central Nervous System | 13 |
| 5 | Urinary Tract | 15 |
| 6 | Genital system | 17 |
| 7 | Blood | |
| 8 | Musculoskeletal | 20 |
| 9 | Еуе | 21 |
| 10 | Ear, nose, and oropharynx | 22 |
| 11 | Skin | 25 |
| Арре | endix 1: Version Control Statements Changes from Version 2 (| June 2013)28 |
| Арре | endix 2 – Consultation Process | |

- 1 -

Introduction

This guidance should be used to determine the choice of initial empirical antibiotic therapy for paediatric patients in acute hospitals in NHS Grampian. This guidance does not cover the choice of empirical antibiotic therapy for all infections and does not replace the need for taking samples to determine the specific causative organism to further direct therapy. Specialist advice will be required for some infections.

This document should not be used to guide therapy if the organism is known and there are specific microbiological sensitivities or if there are other reasons that determine specific antimicrobial therapy, e.g. previous sensitivity testing. The document does not cover the treatment of infections in patients with some chronic disorders or apply in all cases, for example, patients who are immunosuppressed.

If the antibiotic recommended in the guideline is not licensed for the age or indication specified this is stated in the comments column.

Drug interactions should also be considered, for example with macrolides, quinolones, rifampicin, etc – refer to BNF for Children https://www.medicinescomplete.com/mc/bnfc/current/.

Doses

Doses have **not** been included in order to keep this policy brief and easy to read. Prescribers should refer to the BNF for Children <u>https://www.medicinescomplete.com/mc/bnfc/current/</u> or the manufacturers' summary of product characteristics <u>http://www.medicines.org.uk/emc/</u> for information on doses.

Documentation

The reason for prescribing an antimicrobial must be clearly documented in the patient's medical notes together with any relevant signs and symptoms, assessment of severity, microbiology samples taken and results obtained and details of the antimicrobials prescribed. A duration, stop or review date must be clearly documented on the prescription and drug administration record (PAR) for each antimicrobial prescription. For further details please refer to the <u>NHS Grampian Antimicrobial Documentation Policy</u>.

IV to Oral Switch Therapy (IVOST)

Recommendations for intravenous (IV) to oral switches are included in the guidance. Exercise caution when considering a switch to oral in neonates and infants because of the relatively high incidence of bacteraemia and the possibility of variable oral absorption.

Penicillin Allergy

Options for patients with penicillin allergy are included in the guidance – for further information refer to the Guidance for <u>NHS Grampian Staff on Antibiotic Choice for Patients</u> with <u>Penicillin Hypersensitivity</u>. Patients labelled as penicillin allergic should be carefully assessed to determine whether this is a true allergy or an intolerance – for further information refer to the full guidance above.

Tetracyclines

Tetracyclines should **not** be given to children under 12 years as deposition of tetracyclines in growing bone and teeth (by binding to calcium) causes staining and occasionally dental

hypoplasia, (except in exceptional circumstances after discussion with Consultant in Paediatric Infectious Diseases).

Gentamicin and Vancomycin

Advice on dosing and monitoring of gentamicin and vancomycin is available in their respective monographs located in the red paediatric intravenous monograph folder on each ward, on the <u>intranet</u> and/or from the ward pharmacist.

"Consider immune deficiency and testing for HIV"

According to the UK National Guidelines for HIV Testing 2008 (<u>http://www.bhiva.org/HIV-testing-guidelines.aspx</u>) late diagnosis of HIV infection has been associated with increased mortality and morbidity, impaired response to HAART (highly active anti-retroviral therapy), and increased cost to healthcare services. Knowledge of HIV status is associated with a reduction in risk behaviour and therefore it is anticipated that earlier diagnosis will result in reduced onward transmission. One of the categories of patients where routine HIV testing should be offered are those presenting for healthcare where HIV is a possible differential diagnosis – see Table 2 in guidelines link above. Therefore, a recommendation to "consider immune status and HIV testing" has been added to 'indicator infections' included within these guidelines

Advice

Further advice about antimicrobials is available from the on-call Medical Microbiologist, Paediatric Infectious Diseases (PID) Specialist, Ward Pharmacist or Specialist Antimicrobial Pharmacist. Information about who to contact to obtain further specialist advice regarding the treatment of specific infections is given in the relevant section.

| Gastro-Intestinal Tract and Intra-Abdominal Collect appropriate specimens for culture and virology before starting treatment – request <i>C. difficile</i> toxin, ova/cysts if clinically appropriate and note any recent travel | | | | |
|---|---|------------------------------------|------------------------------------|--|
| history on for | | e and virology before starting | g treatment – request C. unici | re toxin, ova/cysts in clinically appropriate and note any recent traver |
| | e specimens if parasitic infe | ction suspected. | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| INFECTION | | | | |
| Infective gastroenteri | is | | | |
| Take infection prever | tion and control precautions | | | |
| Frequently self-limit | ing and may not be bacteria | ıl. | | |
| Antibacterials are <u>n</u> | ot usually indicated. | | | |
| | treatment, if severe systemic liseases specialist advice. | upset/bloody diarrhoea or diar | rhoea in an immunocompromise | ed patient or returning traveller please treat as per microbiology or |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| 1. Gastro-Intestir | . Gastro-Intestinal Tract and Intra-Abdominal (continued) | | | | |
|---|---|---|---|--|--|
| Collect approp history on forr | | re and virology before starting treatment – request <i>C. diffic</i> | ile toxin, ova/cysts if clinically appropriate and note any recent travel | | |
| Clostridium Difficile Infection (Antibiotic associated colitis) | Clostridium difficile | Ensure infection control measures are in place – do not wait for confirmation of diagnosis Send stool sample Stop any (non-Clostridium difficile) antimicrobial treatment in patients with CDI if possible Review any concurrent gastric acid suppressant therapy and reduce or stop if appropriate Review and stop any anti-motility agents to reduce the risk of toxic megacolon development Stop any laxatives for the duration of symptoms Rehydrate patient. Assess symptoms and severity of disease taking into account individual risk factors for the patient Alcohol gel does not kill C difficile spores – follow hand-washing guidance. For further information refer to local policy or <u>Health Protection Network Scottish Guidance</u> (Jan 14 & update October 14). | | | |
| FIRST EPISODE Mild/ Non-severe Severe | _ | Metronidazole oral for 10-14 days If condition does not improve after 5 days, switch to oral vancomycin. Vancomycin oral for 10-14 days | Assess patient daily. Observe bowel movement, symptoms (WBC and hypotension) and fluid balance. If symptoms continue to worsen, refer to gastroenterology/surgery, and discuss with microbiology. | | |
| SECOND OR SUBSEQUENT EPISODE | | Consider adding IV <u>Metronidazole</u> if ileus or hypotension Discuss treatment options with Medical Microbiologist or Paediatric Infection Specialist | | | |

1 Gastro-Intestinal Tract and Intra-Abdominal (continued)

• Collect appropriate specimens for culture and virology before considering treatment – request C. difficile toxin, ova/ cysts if clinically appropriate and note any recent travel history on form.

| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|--|------------------------|---|---|--|
| Appendicitis, Peritonitis, Penetrating abdominal trauma | Coliforms Anaerobes | Gentamicin IV (see monographs) plus Metronidazole IV +/- Amoxicillin IV | In beta-lactam allergy: <u>Clindamycin</u> IV plus <u>Gentamicin</u> IV (see <u>monographs</u>) | Send blood for culture, 2 sets if possible, and pus from operation. Oral switch may not be required depending on duration of IV therapy. Please note: antibiotic surgical prophylaxis for appendectomy should be single dose at induction |
| | | Switch to oral <u>Co-amoxiclav</u> when appropriate. Total duration (IV/oral) 3-7 days depending on degree of contamination and established infection. | Switch to oral <u>Clindamycin</u> when appropriate. Total duration (IV/oral) 3 – 7 days depending on degree of contamination and established infection. | NB Clindamycin is only available as capsules, not suspension |
| Perianal abscess, Pilonidal abscess | Coliforms Anaerobes | For patients with underlying pathology eg inflammatory bowel disease or immune deficiency use triple therapy as for appendicitis above. Co-amoxiclav oral for 3 – 7 days In beta-lactam allergy: clindamycin difference | | Surgical drainage is an important part of managing infected abscesses. NB Clindamycin is only available as capsules, not suspension |
| Pancreatitis | | nitially, often non-infectious origin probiologist. Needs culture of abso | or viral origin. | irect therapy. Send blood for culture. |
| Helicobacter pylori infection – eradication therapy | Helicobacter pylori | Omeprazole oral plus Clarithromycin oral plus Amoxicillin oral for 14 days | Omeprazole oral plus clarithromycin oral plus metronidazole oral for 14 days | Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children 2011 Clarithromycin tablets are not licensed in children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. Omeprazole capsules/tablets are not licensed for use in children except for severe ulcerating reflux oesophagitis in children >1 year. Due to resistance issues if a patient has been treated with clarithromycin in the previous 12 months for any indication consider using a non-clarithromycin based regimen. See NICE guidance <u>for</u> <u>adults (https://www.nice.org.uk/guidance/cg184</u>) or seek local advice for alternatives. |

Identifier: NHSG/Guid/EmpP/MGPG781

| 1 Gastro-Intestinal Tract and Intra-Abdominal (continued) | | | | | | |
|---|------------------|--|------------------------------------|---|--|--|
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments | | |
| Peritoneal dialysis- associated peritonitis | | Treat according to the 'Acute Peritonitis Protocol ' p17 in the Scottish Paediatric Renal and Urology Network Guidelines on the Management of Acute and Chronic Peritoneal Dialysis | | | | |
| Intestinal helminths (worms) | | Mebendazole oral – repeat dose after 2 weeks. | | Treat whole family – can be advised to obtain OTC at a pharmacy. Mebendazole is unlicensed for use in children under 2 years | | |

2. Cardiovascular

- Always take blood for culture before starting treatment for endocarditis if patient is stable, ideally take a minimum of 3 separate blood cultures over a 12 24 hour interval before starting antibiotics; from different venepuncture sites and as close as possible to peak of pyrexia.
- Consult a Cardiologist immediately.
- Consult with paediatric ID specialist and medical microbiologist about organism specific therapy and consider need for urgent surgical intervention.
- Total course of treatment in endocarditis is 4 to 6 weeks. Duration of treatment depends on organism, patient characteristics, presence of prosthetic valve etc.

| INFECTION | Presentation | Antibiotics | Comments |
|------------------------|------------------------------------|--|---|
| Infective endocarditis | Native Valve Endocarditis (NVE) | Amoxicillin IV plus <u>Flucloxacillin</u> IV plus <u>Gentamicin</u> IV (see <u>monographs</u>) | Gentamicin levels must be checked regularly. Age >1 month - <u>multiple daily dosing protocol</u> is used and levels for endocarditis are: Pre-dose (trough) <1mg/L and peak (1 hour post-dose) 3-5mg/L Vancomycin levels must be checked regularly: Pre-dose (trough) level of 10-15mg/L Higher levels may be appropriate in enterococcal endocarditis/MRSA |
| | Penicillin allergy | <u>Vancomycin</u> IV (see <u>monograph</u>) plus <u>Gentamicin</u> IV (see <u>monographs</u>) | Rifampicin helps eradicate bacteria attached to prosthetics |
| | Intra-cardiac prosthesis | Vancomycin IV (see monograph) plus <u>Rifampicin</u> oral plus <u>Gentamicin</u> IV (see monographs) | |

| 2 Cardiovascular | (continued) | | |
|---|---|---|---|
| INFECTION | Presentation | Antibiotics | Comments |
| Sepsis in presence of Central Venous Catheter | Coagulase-negative Staphylococcus spp, Staphylococcus aureus, | Haematology patients: <u>Piperacillin/tazobactam</u> IV | See specific local protocol |
| | gram-negatives | Gastroenterology patients Gentamicin IV (see monograph) plus Teicoplanin IV Neonates Gentamicin IV (see monograph) plus Vancomycin IV (see monograph) All other patients: Flucloxacillin IV plus Gentamicin IV (see monograph) | Blood cultures take from the CVC should be obtained before starting antibiotics. Peripheral blood cultures may help to distinguish catheter-associated infections from bacteraemia in the presence of an intravascular catheter, and may guide the decision when to remove the CVC. If the line is removed, the tip should be sent for culture. If <i>S. aureus</i> is isolated in the blood, the line should be removed and 14 days of appropriate antibiotics given. [Locking lines with antibiotics is not generally recommended – contact microbiology for advice] Gastroenterology patients - refer to Scottish Home Parenteral Nutrition MCN protocol |

| 3 Respiratory System | | | | |
|----------------------|--|--|--|---|
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Influenza | Influenza A & B NB: this guidance refers to seasonal influenza and not pandemic strains | All hospitalised patients with c influenza should receive treatr they are in a high risk group of Please refer to: <u>HPS Influenza guidance A</u> | nent regardless of whether duration since exposure. | Annual vaccination is essential for all those at risk of influenza. |

| 3. Respiratory Syste | em (continued) | | | | | |
|----------------------|--|--|---------------------------|---|-------------------|--|
| | | secretions (or nose and t | hroat swabs in | viral transport m | edium), cons | ider acute and convalescent sera. |
| Collect sputum a | nd blood cultures in pneu | monia if complications a | rise (eg empyen | na, effusion) or if | f patient requ | ires high dependency care. |
| | prior therapy; in patients | | | | | |
| | uld be considered the nor | | | | | e to take oral therapy |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice An | tibiotics | Comments | |
| Bronchiolitis | Respiratory Syncytial Virus Human Metapneumovirus | Not indicated. (Ref <u>SIGN</u> If temperature >38.5°C su | | a and treat accord | dingly. | |
| Community acquired | | pracic Society Guidelines fo | | nt of Community A | Acquired Pneu | imonia in Childhood |
| pneumonia (CAP) | | mmune deficiency or HIV-in | nfection. | | | |
| Mild to moderate | Streptococcus pneumoniae (lobar | Amoxicillin oral | | n penicillin allergy | /: | Consider using oral Penicillin V if organism confirmed |
| | pneumonia) | Total course 5 days | 9 | Clarithromycin or Fotal course 5 da | ral | as sensitive. Clarithromycin tablets are not licensed in children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. |
| Severe | | Neonates: Benzylpenicillin IV plus Gentamicin IV (see mone | <u>ograph)</u> | | | |
| | | Age >1month – 18 yrs Amoxicillin oral/IV If not responding after 48 consider switching to <u>Co-a</u> | hours amoxiclav | n penicillin allergy Age >1 month Cefuroxime orall\ Freat for 7 days. May need to exter on organisms | / nd depending | Only use <u>Clarithromycin</u> if mycoplasma or pertussis (see below) is detected. Clarithromycin tablets are not licensed in children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. |
| | | Treat for 7 days May need to extend depe organisms recovered/ sus | nding on | ecovered/suspect | ted | |

| 3. Respiratory System | n (continued) | | | |
|---|------------------------------------|---|---|---|
| | | I secretions (or nose and th | roat swabs in viral transport n | nedium), consider acute and convalescent sera. |
| Collect sputum and | d blood cultures in pne | umonia if complications ari | se (eg empyema, effusion) or i | if patient requires high dependency care. |
| Always consider p | rior therapy; in patients | s who have not responded t | o a recent course of antibiotic | s consider an alternative agent |
| Oral therapy shoul | d be considered the no | orm except in patients with o | complications, severe sepsis o | or those unable to take oral therapy |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Aspiration pneumonia Consider chemical pneumonitis as a | Mouth flora including anaerobes | Co-amoxiclav Switch to oral Co-amoxiclay. | In penicillin allergy: <u>Cefuroxime</u> IV plus Metronidazole IV | |
| differential diagnosis – | | Treat for 7 days. | Metromdazore IV | |
| antibiotics would not be indicated. | | | Switch to oral <u>Cefuroxime</u> plus oral <u>Metronidazole</u> Treat for 7 days. | |
| Pneumocystis jiroveci (carinii) pneumonia | Pneumocystis jiroveci | Age >6 weeks <u>Co-trimoxazole</u> IV (in severe cases) or orally (non-severe) Treat for 14 - 21 days | Seek specialist advice from PID specialist | Send induced sputum or broncho-alveolar lavage for Pneumocystis PCR and culture to rule out other opportunistic pathogens, e.g. mycobacteria, fungi and viruses. Seek further advice from Consultant Paediatric Infectious Diseases . |
| | | | | Consider immune deficiency or HIV-infection if diagnosis is made in patient without known underlying risk factors |
| Pertussis | Bordetella pertussis | Clarithromycin oral for 7days | | Antibiotics are only indicated if started within 1 week of onset of the paroxysmal cough to reduce transmission. Contact Public Health – notifiable disease. Clarithromycin tablets are not licensed in children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. |
| Hospital-acquired | | Co-amoxiclav IV | | Contact Consultant Paediatrician – Infectious Diseases for advice. |
| pneumonia | | plus Gentamicin IV (see monographs) Treat for 7 – 10 days | | |
| Pulmonary Tuberculosis | Mycobacterium tuberculosis | Refer to PID specialist Send sputum (x3) or gastric treatment. Consider immune deficiency | | w directly after awakening) for culture and sensitivities before starting |
| | | | t regimes and monitoring guidan should be taken half an hour befo | ce. ore breakfast to avoid absorption problems. |

| Central Nervous Send CSF and B | | ric lesions present, a biopsy f | or direct microscopy and c | ulture may be considered. |
|---|--|---|---|--|
| | e from medical microbiol | | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Bacterial meningitis or Meningococcal septicaemia Treatment should not be delayed in suspected cases of bacterial meningitis. | Age <1 month Group B Streptococcus E. coli S pneumoniae Listeria monocytogenes | Age <1 month <u>Cefotaxime</u> IV plus <u>Amoxicillin</u> IV Duration: refer to <u>NICE</u> guideline or <u>BNFC</u> for antibiotic course lengths for appropriate organism. | Seek specialist advice from Paediatric Infectious Diseases Consultant or Medical Microbiology. | SIGN Guideline 102 NICE Guideline CG102 NICE Guideline CG149 Meningitis Research Foundation algorithms - Bacterial Meningitis - Meningococcal Septicaemia |
| Contact Public Health Consultant for advice about | Age >1 month Neisseria meningitides S pneumoniae | Age >1 month <u>Cefotaxime</u> IV | | Amend antibiotics on the basis of microbiology results. |
| secondary cases. | H. influenzae type b | If prolonged or multiple antibiotic use in last 3 months or travel in last 3 months to areas outside UK contact Paediatric Infection Specialist or microbiology for advice. Duration: refer to <u>NICE</u> guideline or <u>BNFC</u> for antibiotic course lengths for appropriate organism. | | If recurrent - consider immune deficiency or HIV infection |
| Brain abscess | Staphylococcus aureus, S. pneumoniae, Streptococcus spp, oral anaerobes | Cefotaxime plus <u>Metronidazole</u> IV Seek neurosurgical advice | | Send blood and aspirate from abscess for culture. Treatment duration and switch to oral therapy is depending on culture results and response. Treatment is at least 4-6 weeks. |

| 4 | Central Nervous System (continued) | | | | | | |
|-------|------------------------------------|---|--|------------------------------------|---|--|--|
| • | Send CSF, bloo | d for culture and PCR for | neurotropic viruses | | | | |
| • | | aryngeal and faeces sampl | | | | | |
| • | Specialist advic | e from medical microbiolo | ogy is essential. | | | | |
| INFEC | CTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments | | |
| Encep | ohalitis | Enteroviruses Parechoviruses Herpes simplex virus | Aciclovir IV for 21 days (if HSV is confirmed) | | Most commonly caused by enteroviruses for which no antiviral treatment is available. Always start with aciclovir until HSV is excluded. Discuss with Paediatric Infectious Diseases Specialist or Medical Microbiology. If recurrent - consider immune deficiency or HIV infection. | | |

| Send blood for cu INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|--|---|--|---|--|
| Lower UTI or acute cystitis Temp <38°C + no systemic signs/ symptoms | Escherichia coli Enterobacteriaceae Staphylococcus saprophyticus | UTI Guideline for RACH <u>NICE – UTI in Children</u> Scottish Paediatric Renal Uro | blogy Network – <u>Policies, Guid</u> a as been taken in the last 3 i | |
| | | days | <u>oeratexin</u> oran or o days | Send MSSU (carefully collected to avoid contamination.) Results of laboratory cultures and sensitivities usually available after overnight incubation. Trimethoprim is not licensed for children <6 weeks |
| Pyelonephritis/Urosepsis Bacteriuria + temp >38°C | Escherichia coli Proteus spp Klebsiella spp | Age <6 months Cefotaxime/ Ceftriaxone* IV Treat for 7-10 days Age >6 months Co-amoxiclav Co-amoxiclav Oral/IV* Add Gentamicin IV (see monograph) if severe infection or unresponsive after 48 hours Switch to oral (Co-amoxiclav) based on sensitivities Treat for 7-10 days | In penicillin allergy: Age >1 month <u>Ciprofloxacin</u> Oral/IV for 7 days Switch to alternative oral option if indicated by microbiology sensitivities. | If >6 months, IV treatment is only required if vomiting or systemically unwell. Prophylactic antibiotics may be considered if recurrent UTIs (see below) * Contraindications to <u>Ceftriaxone</u> IV All ages: simultaneous administration of calcium-containing infusions but can be given sequentially as long as infusion line flushed between infusions or a different infusion line is used. Children <1 month: prematurity, jaundice, acidosis Ciprofloxacin is not licensed for children <1 year. Trimethoprim is not licensed for children <6 weeks |

| 5 Urinary Tract (co | Urinary Tract (continued) | | | | | | |
|---------------------|---------------------------------------|--|---|--|--|--|--|
| Samples should | be taken prior to starting | y treatment | | | | | |
| Send blood for c | ulture if pyrexial. | | | | | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments | | | |
| Catheter UTI | Escherichia coli Enterobacteriacea | count or acute confusion. Smelly or cloudy urine, bacteru indications for changing the ca If systemic infection is likely, tr Evidence suggests that cathete | dicated unless the patient has uria without systemic symptom theter. eat as for pyelonephritis. er change prior to treatment r | ry common. evidence of systemic infection, e.g. pyrexia, loin pain, raised white cell ns or catheter blockage are not indications for antimicrobials but are results in more rapid symptom resolution and lower rates of treatment nd start antibiotics if symptomatic. | | | |

| 6 | Genital syste | əm |
|---|---------------|----|
|---|---------------|----|

• If STD is suspected patients <13 years should be referred to the RACH Child Protection Team and patients >13 years should be referred to Sexual Health (0845 337 9900)

• Send blood for culture if pyrexial

| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|-------------------------------------|------------------|---|--|--|
| Vulvo and/or vaginal Candidiasis | Candida albicans | Clotrimazole 1% cream and/or | | Intravaginal treatment should generally be avoided in pre-pubertal girls; oral treatment may be more appropriate. |
| | | Females age 12 – 16 years Fluconazole oral for 1 – 3 days | | Oral triazoles are usually recommended for the treatment of genital candidiasis in girls aged 12 – 16 years although fluconazole is not licensed for vaginal candidiasis in girls <16 years. |
| Infective balanitis | Candidal | Clotrimazole 1% cream topically twice daily until symptoms settle | For severe symptoms: Fluconazole oral | If cellulitis develops then refer to cellulitis section and take appropriate swabs. |
| | Bacterial | Usually antibiotics not required. | | To reduce the risk of subsequent infections, patients/carers should be advised to avoid potential irritants and ensure good penis hygiene. |

| INFECTION | as possible, within 1 hour of diagnosis 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|---|---|---|--|
| Sepsis or feverish illness – unknown source Refer to Sepsis 6 guideline | Neonates Community acquired: Cefotaxime IV plus Amoxicillin IV Neonates Nosocomial: Gentamicin IV (see monograph) plus Vancomycin IV (see monograph) Age >1 month Cefotaxime IV | Age >1 month In penicillin allergy: <u>Gentamicin</u> IV (see <u>monograph</u>) plus Vancomycin IV (see <u>monograph</u>) | Seek advice from Medical Microbiology or PID specialist. Prompt diagnosis vital to allow early rationalisation of treatment. The most common causes of sepsis are urinary or respiratory sources which should be treated according to the relevant sections in this guideline Sepsis may be masked in immunosuppression and in the presence of anti-inflammatory drugs and beta-blockers. Give IV antibiotics to • Infants <1 month with fever • All infants aged 1- 3 months with fever who appear unwell • Infants aged 1-3 months with fever who appear unwell • Infants aged 1-3 months with WBC <5 x 10 ⁹ /L or >15 x 10 ⁹ /L • Children >3 months with fever who are shocked, unrousable or have signs of meningococcal disease (see section 4) Consider IV antibiotics for • Children >3 months with fever and reduced consciousness If herpes simplex suspected, add Aciclovir IV If known MRSA carrier give: Vancomycin IV (see monograph) plus Gentamicin IV (see monograph) plus Gentamicin IV (see monographs) If recurrent, consider immune deficiency or HIV infection NICE Guideline 160 – Feverish Illness in Children May 2013 NICE Guideline 149 – Antibiotics for early-onset neonatal infection Aug 2012 |
| Toxic Shock Syndrome | Flucioxacillin IV plus <u>Gentamicin</u> IV (see <u>monographs</u>) +/- Clindamycin IV | | |
| Meningococcal septicaemia | | | |
| - Refer to section 4 | | | |

| 7 Blood (continued) | | | | |
|--|---|------------------------------------|---|--|
| Take blood and urin | e cultures before starting t | reatment, plus swabs from a | ny other focus of infection | n, e.g. sputum, wound swabs, etc. |
| Give antibiotics as a | soon as possible, within 1 h | our of diagnosis of sepsis. | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Neutropenic sepsis Neutrophil count ≤1.0 x 10 ⁹ /L | Gram-negatives S. aureus S. epidermidis | Piperacillin/tazobactam IV | In penicillin allergy: <u>Meropenem</u> IV | Refer to NICE Guideline 151 Add Gentamicin IV (see monographs) if advised by consultant |
| Temperature: >38°C x 3 in 4-6 hours Or single pyrexia >39°C Or shaking chill or rigor associated with fever | | | | Add <u>Teicoplanin</u> IV if fever and/or rigors after line flushed earlier in day or soon after new line inserted. Piperacillin/tazobactam is not licensed for children <2 years for neutropenic sepsis. |

| e maccarconen | | | | |
|--------------------|---------------------------|------------------------------------|------------------------------------|--|
| | - | - | | n orthopaedic surgeon and paediatric infectious diseases specialist. |
| Duration of tr | reatment is guided by c | ultures and effectiveness | of local drainage. | |
| Septic arthrit | is is managed by surgio | cal drainage supported by | antibiotic treatment and o | drainage may be required for osteomyelitis as well. |
| Send blood a | ind bone aspirate/joint f | luid for culture prior to st | arting antibiotics. | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Acute | < 6 months S. aureus, | If age <6 months | In penicillin allergy: | Immediate consultation by Orthopaedic Surgeons is essential |
| Osteomyelitis / | S. pyogenes | Cefuroxime IV | Vancomycin IV (see | |
| Septic arthritis / | E. coli | IV | monograph) | |
| Acute discitis / | S. agalactiae (GBS) | plus | plus | If MRSA likely use: |
| Deep myositis | | Gentamicin IV (see | Gentamicin IV (see | Vancomycin IV (see monograph) as 1 st choice. |
| | | <u>monographs</u>) | <u>monographs</u>) | |
| | | | In penicillin allergy: | Pseudomonas likely in feet infections and sickle cell anaemia at any age |
| | If age >6 months | If age > 6 months | Clindamycin IV | |
| | Staphylococcus | Flucloxacillin IV | OR | If Pseudomonas likely in puncture associated infections use: |
| | aureus | +/- | Ciprofloxacin IV | Ceftazadime IV |
| | | Gentamicin IV (see | | |
| | | monographs) | | |
| | Consider MRSA | | | Initial IV therapy is required but a switch to oral therapy can be considered once |
| | | | | the patient is apyrexial for 48 hours, local symptoms have improved, and |
| | | | | inflammatory markers are decreasing. |
| | | | | Minimum treatment duration is 4 -6 weeks. |
| | | | | |
| | | | | If recurrent - consider immune deficiency or HIV-infection. |
| | | | | |
| | | | | |

8

Musculoskeletal

| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|---|---|--|---|--|
| Conjunctivitis, purulent | Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus spp Moraxella catarrhalis | Chloramphenicol 0.5% eye drops +/- Chloramphenicol 1% eye ointment, For 7 days or until symptom free for 48 hours | Fusidic acid 1% viscous eye drops For 7 days or until symptom free for 48 hours | Fusidic acid has less Gram negative activity. Remove contact lenses until all symptoms and signs of infection resolved and treatment complete for 24 hours. |
| Orbital cellulitis | Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus | Ceftriaxone IV plus Metronidazole IV For 10 days total treatment – if intracranial pathology excluded and child responds well to IV, switch to oral <u>Co-amoxiclav</u> after 3-5 days | In severe penicillin allergy: <u>Ciprofloxacin</u> IV plus <u>Clindamycin</u> IV For 10 days total treatment – if intracranial pathology excluded and child responds well to IV, switch to oral <u>Ciprofloxacin</u> + <u>Clindamycin</u> (de-escalate to one antibiotic if possible) after 3-5 days | Serious emergency – infection of soft tissues behind orbital septum. Contact Infectious Diseases specialist for advice regarding duration if there is evidence of intracranial extension or if the child has had surgery. |
| Pre-septal cellulitis (peri-orbital) | Staphylococcus aureus, Streptococcus pneumoniae, | Flucloxacillin oral | In penicillin allergy: Clindamycin oral | Infection anterior to the orbital septum. Clindamycin suspension is no longer available; clarithromycin may be used as an alternative for patients who require a liquid. NB Clarithromycin suspension is not licensed in infants <6 months. |
| Dacrocystitis | | Only treat in moderate/severe cases Flucloxacillin oral | | Inflammation of the lacrimal sac. |
| Dacroadenitis | Viral most common, bacterial, protozoan, fungal, non-infectious | Warm compresses and analgesia if viral. Cephalexin oral if bacterial. | | Inflammation of the lacrimal gland. Review need for antibiotic once culture results available. |
| Ophthalmic zoster | Varicella Zoster | Aciclovir oral for 7 days | Liaise with Ophthalmology for | or specialist advice |

| 10 Ear, nose, and o | oropharynx | | | | | | |
|--|---|---|--|--|--|--|--|
| | e samples for culture and/ | | | | | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments | | | |
| Otitis externa | If not the presenting compl | aint and non-severe then refer to <u>primary care guidance</u> on otitis externa. | | | | | |
| Consider systemic antibacterial if | Staphylococcus aureus | Aural toilet | Aural toilet | Send aspirate or swab. | | | |
| spreading cellulitis or patient systemically unwell (flucloxacillin or | | + Analgesia | * * <u>Betamethasone 0.1%</u> and Neomycin 0.5% (Betnesol-N [®]) ear/eye | *Betamethasone and neomycin is contra-indicated in patients with a perforated tympanic membrane. | | | |
| erythromycin) or if pseudomonas | | | drops, for 7 days | Products to consider in mild cases (in addition to aural toilet) include Sofradex [®] , Locorten-Vioform [®] . | | | |
| suspected (ciprofloxacin) | | | | Consider systemic antibacterial if spreading cellulitis or patient systemically unwell (flucloxacillin or erythromycin). | | | |
| | Pseudomonas aeruginosa | Aural toilet plus | Ciprofloxacin 0.3% eye drops**, apply 2 drops into | Seek ENT, medical microbiology advice. | | | |
| | | * <u>Gentamicin</u> 0.3% ear drops for 3-5 days | the ear three times daily. | *Gentamicin is contra-indicated in patients with a perforated tympanic membrane. | | | |
| | | | More serious infection: Add <u>Ciprofloxacin</u> orally for 5 days | ** There are no licensed ciprofloxacin ear drops available in the UK. Ciprofloxacin eye drops can be used off-label in the ear. The dose is based on advice from ENT, for more information see <u>SmPC</u> . | | | |
| | | | | Oral ciprofloxacin is not licensed for children <1 year | | | |
| | Fungal: <i>Candida</i> spp, moulds (e.g. <i>Aspergillus</i> spp.) | Aural toilet plus <u>Clotrimazole</u> 1% solution for at least 14 days after disappearance of infection. | | Seek specialist advice if required | | | |
| Patients day dela You nee | | day delayed or immediate anti | teria (history of fever, purulent ibiotics. > >4000 patients to prevent one | tonsils, cervical lymphadenopathy, absence of cough) consider a 2-3 e quinsy, and to 200 patients to prevent one otitis media. | | | |
| | | Consider antibacterial, if histor increased risk from acute infe | | marked systemic upset, if peritonsillar cellulitis or abscess, or if at cystic fibrosis). | | | |
| Tonsillitis | Streptococcus pyogenes | Penicillin V oral, if unable to swallow use Benzylpenicillin IV. | In penicillin allergy: Clarithromycin oral , if unable to swallow then use | Send bacterial throat swab blood for EBV serology if indicated. Clarithromycin tablets and intravenous infusion are not licensed in | | | |
| | | Total duration of 10 days | IV. Total duration of 10 days | children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. | | | |

| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|--|--|--|---|--|
| Quinsy (peritonsillar abscess) | Polymicrobial | Penicillin V oral, if unable to swallow use Benzylpenicillin IV Total duration of 10 days | In penicillin allergy: <u>Clindamycin</u> oral, if unable to swallow then use IV. Total duration of 10 days | Consult ENT as will require aspiration and drainage. |
| Mastoiditis | Streptococcus pneumoniae Moraxella catarrhalis Group A Streptococcus | Co-amoxiclav IV then switch to oral for 10 days | Contact Paediatric Infectious Diseases Consultant for advice. | |
| Acute otitis media (Many are viral. Illness resolves over 4 days in 80% without antibiotics) | Streptococcus pneumoniae Moraxella catarrhalis Group A Streptococcus | deafness. Optimise analgesia. Antibacterial treatment may be | e started after 72 hours if no in eterioration, if systemically unv in children under 2 years of ag | |
| | | Amoxicillin oral for 5 days Severe Infection <u>Co-amoxiclav</u> Oral/IV | In penicillin allergy: <u>Clarithromycin</u> oral for 5 days Severe infection <u>Cefuroxime</u> IV | Send aspirate or exudates if drum is perforated. Haemophilus spp are extracellular pathogens, thus macrolides, which concentrate intracellularly, are less effective treatment. Clarithromycin tablets are not licensed in children under 12 years; suspension is not licensed for use in infants <6 months. |
| Chronic otitis media - seek ENT advice | | 1 | | |
| Acute sinusitis (Many are viral) | Streptococcus pneumoniae Moraxella catarrhalis Group A Streptococcus | <u>Amoxicillin</u> oral for 7 days Use IV initially in severe/ febrile cases | In penicillin allergy, <u>Clarithromycin</u> oral for 5 days | In acute sinusitis prescribe 6 – 12 years <u>Xylometazoline</u> 0.05% nasal drops for 5 days. 12 – 18 years <u>Xylometazoline</u> 0.1% nasal drops for 5 days. Send aspirate, discharge or antral washings. |
| Chronic sinusitis | Streptococcus pneumoniae Haemophilus influenzae Staphylococcus aureus Anaerobes, Fungi | Base treatment on culture results | Consult medical microbiology and ENT surgeon | Take nasopharyngeal swab if no other samples obtained. Also consider intranasal steroids +/- decongestant see MHRA guidance on cough and cold treatments in children. Limit treatment to one course only. Refer to ENT. |

| 10. Ear, nose, ar | nd oropharynx (continued) | | | |
|-------------------|---------------------------------------|---|--|--|
| Take approp | priate samples for culture ar | nd/or viral PCR | | |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Oral thrush | Candida albicans | Nystatin oral suspension, usually for 7 days. Continue for 48 hours after lesions have resolved. Immunocompromised; <u>Fluconazole</u> oral for 7 – 14 days | Miconazole oral gel for 5 – 7 days. Continue for 48 hours after lesions have resolved. The gel should be placed at the front of the mouth to avoid the risk of choking – never put it at the back of the throat. | Send scrapings for culture. If recurrent - Consider immune deficiency or HIV-infection. NB Miconazole is not licensed for children under 4 months of age or during the first 5 – 6 months of life of an infant born pre-term. Nystatin is not licensed for neonates. |
| Dental abscess | <i>Streptococcus</i> spp Anaerobes | Penicillin V oral or Zmoxicillin oral for 5 days If spreading infection or pyrexia: add <u>Metronidazole</u> oral | <u>Metronidazole</u> oral for 5 days | Refer to <u>SDCEP Drug Prescribing in Dentistry</u> |

| 11 Skin | | | | |
|----------------------|---|---|---|---|
| Take appropriate | e specimens before starting t | herapy, consult dermatologist ar | nd medical microbiologist for pa | atients with severe or recurrent infections |
| | | on, tetanus prophylaxis and topi | | |
| | | | | dence of infection, e.g. cellulitis, discharge or acute pain |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Cellulitis | Streptococcus pyogenes Staphylococcus aureus | Flucloxacillin Oral/IV Switch to oral Flucloxacillin | In penicillin allergy: <u>Clindamycin</u> Oral/IV, | Longer courses may be required in severe infections. |
| | | for 7-14 days | switch to oral for 7-14 days | If MRSA is likely use: <u>Vancomycin</u> IV as 1 st choice (see <u>monograph)</u> |
| | | | | Send blood for culture. |
| | | | | Clindamycin suspension is no longer available; clarithromycin may be used as an alternative for patients who require a liquid. Clarithromycin suspension is not licensed for use in infants <6 months. |
| | | | | ft tissue infections including boils, carbuncles, folliculitis, cellulitis, ps.scot.nhs.uk/about-hps/hpn/pvl-guidance.pdf |
| | -, | g | | |
| Neonatal Umbilical | Staphylococcus aureus | Flucloxacillin IV/oral | | |
| Infection – purulent | | If severe, add | | |
| discharge | | Gentamicin IV (see | | |
| | | <u>monograph</u>) | | |
| Impetigo | Staphylococcus aureus | If localised, | If widespread, | Send swabs or scrapings for culture. |
| | | Fusidic acid 2% cream, for | Flucloxacillin oral for 7 | |
| | | 5 days | days | Clarithromycin tablets are not licensed in children under 12 years. Clarithromycin suspension is not licensed for use in infants <6 |
| | | If MRSA | In penicillin allergy: | months. |
| | | suspected/isolated, | Clarithromycin oral for 7 | |
| | | Mupirocin 2% ointment for | days | |
| | | 5 days | | |
| | | | If MRSA | |
| | | | suspected/isolated seek | |
| | | | advice from PID specialist | |
| | | | or microbiology | |

| 11. Skin (continued | l) | | | |
|--|---|--|---|--|
| | | | | patients with severe or recurrent infections |
| | | on, tetanus prophylaxis and top | | dence of infection, e.g. cellulitis, discharge or acute pain |
| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
| Bites – Animal | Pasteurella multocida anaerobes | Co-amoxiclav oral for 7 days | In penicillin allergy: Age > 6 months and <12 years <u>Co-trimoxazole</u> oral plus <u>Metronidazole</u> oral for 5 days In penicillin allergy: Age >12 years <u>Doxycycline</u> oral plus <u>Metronidazole</u> oral | Send blood and swabs for culture. NB Co-trimoxazole is not licensed for the treatment of bites but it is recommended as it provides good coverage of the likely causative organisms, has a low risk of antibiotic associated diarrhoea and is available in both tablets and suspension NB: prophylaxis tetanus and rabies < 6 months: consult paediatric infectious diseases specialist or microbiology |
| Bites – Human | Streptococcus pyogenes Staphylococcus aureus Oral anaerobes | Co-amoxiclay oral for 7 days | for 5 days. Clarithromycin oral plus(if severe) <u>Metronidazole</u> oral for 7 days | Send blood and swabs for culture. Clarithromycin tablets are not licensed in children under 12 years; clarithromycin suspension is not licensed for use in infants <6 months. |
| Post- operative wound infections - abdominal, female genital tract, head and neck "Dirty sites" | Staphylococcus aureus Anaerobes | Co-amoxiclav oral for 7 days | In penicillin allergy, <u>Clindamycin</u> oral for 7 days | If collection present will require surgical drainage. It is important to base treatment on microbiology sensitivities where available. Route of administration is dependent on the severity of infection and |
| Post- operative wound infections – excluding abdominal, female genital tract, head and neck "Clean sites" | Staphylococcus aureus | Flucloxacillin oral for 7 days | In penicillin allergy: Clindamycin oral for 7 days | ability of patient to take medication orally Clindamycin suspension is no longer available. Clarithromycin suspension may be used as an alternative for patients who require a liquid but it is not licensed for use in infants <6 months. |

| INFECTION | Likely organisms | 1 st Choice Antibiotics | 2 nd Choice Antibiotics | Comments |
|-----------|------------------------------|---|------------------------------------|--|
| Scabies | Sarcoptes scabiei | Permethrin 5% dermal cream, apply to the whole body (see note*), taking care to treat the webs of fingers and toes and under the nails. Wash off after 8 - 12 hours. Re-apply to hands if washed within 8 hours of application. Repeat after 7 days. | | Send scrapings for culture. Treat all household contacts simultaneously. *Manufacturers recommend that some patient groups do not require treatment above the neck but BNFC, HPA and CKS all recommend to include scalp, face, neck and ears in all patients. Permethrin cream is not licensed for use in children <2 months and medical supervision is required for children aged < 2 years. |
| Crab Lice | Phthirus pubis | Permethrin 5% cream, apply over whole body and should be left on the skin for 24 hours*. The treatment areas should then be thoroughly washed. Reapply after 7 days. | | Pay particular attention to the pubic hair, hair around the anus, between the legs, and other hairy areas of the body. Check for involvement of more distant sites such as eyebrows. See CKS for further information: <u>http://cks.nice.org.uk/pubic-lice</u> Note: re-application of permethrin is based on expert opinion and has been accepted as standard practice, although not licensed. [*Also, BNFC recommends 12 hour contact time instead of licensed recommendation of 24 hours] Permethrin cream is not licensed for use in children <2 months and medical expeription is previoud for children expeription. |
| Head Lice | Pediculus humanus capitis | Dimeticone 4% lotion Apply sufficient lotion to cover dry hair from the base to the tip to ensure no part of the scalp is left uncovered. Leave on hair for a minimum of 8 hours or overnight. Wash out with normal shampoo and rinse thoroughly. Treatment must be reapplied after 7 days to ensure any lice that hatch following the first application are killed. | | supervision is required for children aged < 2 years. NHS Grampian does not recommend rotating between insecticides. Dimeticone 4% lotion is not licensed for use in children <6 months. |

Appendix 1: Version Control Statements Changes from Version 2 (June 2013)

Introduction

Added note about considering drug interactions; note on carefully assessing patients to differentiate between penicillin allergy and intolerance; section recommending consideration of immune status and HIV testing for indicator infections in line with BHIVA guidelines; update of link for BNFC; amendment to tetracycline caution so that it can be used in exceptional circumstances; and deletion of quinolone warning.

Section 1 - Gastrointestinal

- Salmonella spp: delete comment 'Treat less severe infection in children under 6 months, haemoglobinopathy or if immunocompromised' and add 'Antibiotic therapy may be considered in children under 6 months in the presence of haemoglobinopathy or if immunocompromised.' to 1st choice antibiotic column.
- Clostridium Difficile Infection: general advice updated in line with recommendations from <u>HPS guidance Oct</u> <u>2014</u>. Added 'Second or subsequent episode – Discuss treatment options with Medical Microbiologist or Paediatric Infection Specialist.'
- Appendicitis (etc): for 2nd choice antibiotics add clindamycin as oral switch and note that clindamycin is only available as capsules, not suspension.
- Perianal/Pilonidal abscess: new indication for patients with underlying pathology eg inflammatory bowel disease or immune deficiency use triple therapy as for appendicitis. For all others: coamoxiclav 1st line, clindamycin if beta-lactam allergy. Note in comments 'Surgical drainage is an important part of managing infected abscesses.'
- H pylori: added comment 'Due to resistance issues if a patient has been treated with clarithromycin in the previous 12 months for any indication consider using a non-clarithromycin based regimen. See <u>NICE</u> <u>guidance</u> or seek local advice for alternatives.'
- Inflammatory Bowel Disease: indication removed

Section 2 - Cardiovascular

 Native Valve Endocarditis – Amoxicillin + Gentamicin (optional) changed to Amoxicillin + Flucloxacillin + Gentamicin based on 2015 European Society of Cardiology Guidelines for the management of infective endocarditis

http://eurheartj.oxfordjournals.org/content/early/2015/ 08/28/eurheartj.ehv319

 Sepsis in presence of CVC: gram-negative organisms added to likely organisms. Comment about taking blood cultures expanded. Non-haematology patients changed to Gastroenterology patients: Gentamicin + Teicoplanin and refer to MCN protocol; Neonates: Gentamicin + Vancomycin; all other patients: Flucloxacillin + Gentamicin.

Section 3 – Respiratory

 Influenza – updated with HPS guidance and confirmation that 'All hospitalised patients with confirmed or suspected influenza should receive treatment regardless of whether they are in a high risk group or duration since exposure.' Dosing information for oseltamivir removed – information in BNFC – linked. Advice regarding prophylaxis removed – link to HPS guidance should be sufficient.

- Bronchiolitis: 'not recommended routinely' changed to 'not indicated'.
- Community-acquired pneumonia mild to moderate: deleted 'If not improving after 48 hours check for mycoplasma, add Clarithromycin oral for 10 days.' Duration changed from 3-5 days to 5 days.
- CAP severe: oral options listed as per BTS guideline. Duration changed from 7 – 21 days to 'Treat for 7 days. May need to extend depending on organism recovered/suspected.' Comment about adding clarithromycin changed to 'Only use clarithromycin if mycoplasma or pertussis (see below) is detected. Clarithromycin removed from empirical option.
- Aspiration pneumonia: add 'Consider chemical pneumonitis as a differential diagnosis – antibiotics would not be indicated.'
- Pertussis: new indication clarithromycin oral for 7 days. Antibiotics are only indicated if started within 1 week of onset of the paroxysmal cough to reduce transmission. Contact Public Health – notifiable disease.
- Hospital-acquired pneumonia: new indication coamoxiclav + gentamicin. Contact Consultant Paediatrician – Infectious Diseases.
- Meconium aspiration indication removed
- Post-operative chest infection indication removed
- Infected Exacerbation in a Cystic Fibrosis patient removed as patients not treated empirically.
- Pulmonary Tuberculosis amended advice on sputum and gastric lavage sampling.

Section 4 – CNS

- General notes: sampling simplified to 'Send CSF and blood for culture. If purpuric lesions present, a biopsy for direct microscopy and culture may be considered.
- Bacterial Meningitis (etc) age ranges changed from </>> 3 months to </>> 1 month. Advice about adding vancomycin changed to seek specialist advice. Comment about switching to ceftriaxone removed. Contraindications to ceftriaxone removed.
- Brain abscess: suspected organisms coliforms removed, S Pneumonoccus changed to S pneumonia.
- Encephalitis: Sampling advice moved from comments column to general notes and amended to 'Send CSF, blood for culture and PCR for neurotropic viruses. Obtain nasopharyngeal and faeces samples for viral PCR.' Likely organisms: added enteroviruses and parechoviruses. Comments: added 'Most commonly caused by enteroviruses for which no antiviral treatment is available. Always start with aciclovir until HSV is excluded.

Section 5: Urinary Tract

- Lower UTI/acute cystitis: general comment changed to 'If trimethoprim/cefalexin has been taken in the last 3 months then select an alternative antibiotic based on previous microbiology sensitivities, if available.' Oral switch changed from trimethoprim to coamoxiclav and based on sensitivities.
- · Prophylactic indications removed.
- Catheter UTI: comments amended 'Smelly or cloudy urine, bacteruria without systemic symptoms or catheter blockage are not indications for antimicrobials but are indications for changing the catheter.'

Section 6 – Genital System

Infective balanitis: comment added 'To reduce the risk of subsequent infection, patients/carers should be

UNCONTROLLED WHEN PRINTED Review Date: October 2017 Identifier: NHSG/Guid/EmpP/MGPG781 Empirical Therapy Guidance for Common Infections in Children in the Acute Sector – Version 3.2 advised to avoid potential irritants and ensure good penis hygiene.' Advice about analgesia removed.

Section 7 – Blood

- Sepsis of unknown source: advice on when to use IV antibiotics and NICE guideline links moved to comments column. 'Refer to Sepsis 6 guideline' added to first column. Neonates – communityacquired: 1st choice antibiotics changed from Benzylpenicillin + Gentamicin to Cefotaxime + Amoxicillin. (In order to cover meningitis and align with A&E sepsis 6 guideline.) 2nd choice antibiotic option removed. >1month: changed from Cefotaxime + Amoxicillin to Cefotaxime alone. (Risk of listeria is very low >1 month)
- Comments on changing to ceftriaxone and contraindications to ceftriaxone removed.
- Comment amended in line with adult guidance: 'The most common causes of sepsis are urinary or respiratory sources which should be treated according to the relevant sections in this guideline.'
- If known MRSA carrier: changed from vancomycin + gentamicin +/- metronidazole to vancomycin + gentamicin.
- Toxic Shock Syndrome: new indication 1st choice antibiotics: flucloxacillin + gentamicin +/- clindamycin
- Neutropenic sepsis: likely organisms amended to gram-negatives, S. Aureus and S.epidermidis. Mild penicillin allergy changed to penicillin allergy and 2nd choice changed from ceftazidime to meropenem.

Section 8 – Musculoskeletal

Indication amended to 'Acute osteomyelitis/septic arthritis/acute discitis/deep myositis'.: Age range changed to <6 months: Likely organisms amended to S aureus, S pyogenes, E coli, S agalactiae (GBS); 1st choice antibiotics changed from flucloxacillin + cefuroxime to cefuroxime + gentamicin. >2 years 1st choice antibiotics changed from flucloxacillin + sodium fusidate to flucloxacillin + gentamicin and in penicillin allergy vancomycin changed to clindamycin or ciprofloxacin. Comments changed to 'Initial IV therapy is required but a switch to oral therapy can be considered once the patient is apyrexial for 48 hours, local symptoms have improved, and inflammatory markers are decreasing. Amended comment re pseudomonas to add 'in puncture associated infections' use ceftazidime IV.

Section 9 – Eye

- Neonatal gonococcal conjunctivitis cefotaxime IM changed to IV. Comment regarding ofloxacin eye drops removed.
- New indications: orbital cellulitis, preseptal cellulitis, dacrocystitis, dacroadenitis and ophthalmic zoster.

Section 10 - ENT

- Otitis Externa Gentisone HC no longer available changed to Betamethasone 0.1% and Neomycin 0.5% ear/eye drops. Comment added to align with adult guideline 'Products to consider in mild cases (in addition to aural toilet) include Sofradex[®], Locorten-Vioform[®]. Consider systemic antibacterial if spreading cellulitis or patient systemically unwell (flucloxacillin or erythromycin).
- Tonsilitis: removed comment regarding avoidance of amoxicillin and ampicillin in glandular fever.
- Mastoiditis: new indication
- Oral thrush age ranges removed. Licensed age restrictions added to comments.

Section 11 – Skin

- Cellulitis: 1st choice changed from flucloxacillin + benzylpenicillin to flucloxacillin alone; penicillin allergy changed from vancomycin IV switching to clarithromycin oral to clindamycin oral/IV
- Panton-Valentine Leukocidin associated Staphylococcus aureus infections – advice about when to consider and link to HPN guidance.
- Abscess indication removed
- Post-op wound 'dirty sites' penicillin allergy option added: clindamycin oral for 7 days
- Post-op wound 'clean sites' penicillin allergy option changed from clarithromycin to clindamycin
- Scables notes added to align with adult guideline. Malathion removed as 2nd line option (no longer stocked in hospital.)
- Crab lice 1st line option changed from malathion to permethrin and notes amended
- Head lice 1st line option changed from malathion to dimeticone 4% lotion and notes amended. Link to HPS document removed as no longer available.

Appendix 2 – Consultation Process

This policy was re-drafted by the following group:

| Professor Adilia Warris | Paediatric Infectious Diseases Specialist |
|-------------------------|---|
| Dr Ian Gould | Consultant Microbiologist |
| Mrs Gillian Macartney | Specialist Antimicrobial Pharmacist |
| Mrs Fiona McDonald | Specialist Antimicrobial Pharmacist |
| Mrs Jenny Mosley | Clinical Pharmacy Team Leader, RACH |
| Mr Yatin Patel | Consultant Paediatric Surgeon |
| Dr Timothy Lawes | Foundation Year 2 Doctor, RACH |

This policy was sent to the following via email for comment:

Dr Catherine Hauptfleisch Consultant, Neonatal Unit

This policy was also sent to the following groups via email for comment:

- All consultants at RACH via the Combined Child Health Senior Staff Committee Sep 2015
- All pharmacists at RACH and Dr Gray's paediatric ward

Comments were received from:

Isobel Morrison Clinical Pharmacist - AMH

This policy has been reviewed and agreed by:

- NHS Grampian Antimicrobial Group September 2015
- NHS Grampian Medicines Guidelines and Policies Group October 2015